ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Conversion to a Belatacept Based Immunosuppression Regimen in Renal Transplant Recipients

K. Paplaczyk, K. Cunningham, C. D'Agostino, D. Pinelli, J. Schulte, A. Shetty

Northwestern Memorial Hospital, Chicago, IL

Meeting: 2020 American Transplant Congress

Abstract number: 116

Keywords: Antibodies, Immunosuppression, Kidney

Session Information

Date: Saturday, May 30, 2020

Session Name: Novel Immunosuppression: Belatacept

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:27pm-4:39pm

Location: Virtual

Related Abstracts
  • Lower Frequency of Regulatory T-Cells After Conversion from CNIs or mTORi to Belatacept in a Prospective Matched Controlled Study in Renal Allograft Recipients
  • Early Conversion to Belatacept in High Risk Renal Transplant Recipients

*Purpose: Belatacept, a co-stimulation blocker, is an alternative anti-rejection agent that may avoid nephrotoxic or intolerable adverse effects of calcineurin inhibitor (CNI) or mammalian target of rapamycin inhibitor (mTORi) based regimens and has shown to preserve long-term renal function. Recent data has demonstrated improvement or stabilization of pre-existing donor specific antibodies (DSA) in belatacept treated patients. This study evaluates the impact of conversion to belatacept on renal function and DSA.

*Methods: This is a single center, retrospective review of adult renal transplant recipients converted to belatacept. Patients were excluded if they received a multi-organ transplant or did not reach maintenance dosing for belatacept. Trends in DSA and eGFR at 12 months after conversion were assessed.

*Results: Fifty-two patients were analyzed. Median time to belatacept conversion was 427 days post-transplant (IQR 98-525). Serum creatinine changed from a mean 2.1±1.5mg/dL at time of conversion to 1.6±0.6mg/dL at 12 months (P=0.0675). Mean eGFR at time of conversion was 44.1±23.2ml/min and changed to 51.1±21.7ml/min at month 12 post-conversion (P=0.1422). Rejection occurred in 17 patients (32.7%) post conversion. Sixteen experienced borderline rejection; 4 of which were treated with steroids. One patient experienced Banff 1A rejection and was treated with steroids. No patients developed PTLD within one year of conversion. Four patients had detectable DSA prior to transplant with 6 additional patients developing de novo DSA post-transplant but prior to belatacept conversion. Nine of 10 patients with DSA prior to belatacept conversion experienced either decreased DSA titers or DSA stabilization after initiating belatacept. No patients developed de novo DSA post-belatacept conversion.

*Conclusions: Conversion to belatacept was associated with a similar eGFR at 12 months in kidney transplant patients who had previously been on CNI or mTORi based immunosuppression. Following belatacept conversion, patients with detectable DSA were found to either have decreased or stabilization of DSA titers. Conversion to belatacept may be a desirable option for patients who have intolerance to CNI or mTORi based regimens. Analysis in a larger number of patients should be evaluated.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Paplaczyk K, Cunningham K, D'Agostino C, Pinelli D, Schulte J, Shetty A. Conversion to a Belatacept Based Immunosuppression Regimen in Renal Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/conversion-to-a-belatacept-based-immunosuppression-regimen-in-renal-transplant-recipients/. Accessed March 6, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation
    • Factors Influencing Creatinine Rise Following Donor Nephrectomy

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.